₹227.14
−0.66%NSE close, 16 Nov 2026
−12.96%
Indoco Remedies is a small cap company, listed on NSE under the symbol INDOCO. At ₹227.14 a share, the market values the whole company at ₹2,097 crore.
In FY26, it reported sales of ₹1,845 crore and a net loss of ₹95 crore, an operating margin of 7.7%. Over the last three years, sales grew 3.4% a year.
The market values the company at 65.6 times its profit over the last twelve months and 2.05 times its book value; its return on equity is 3.1% and its borrowings are 0.96 times its equity.
Promoters hold 58.92% of the shares. Foreign institutions hold 1.64%, and domestic institutions, mutual funds among them, 16.64%.
Over the past year the share price has fallen 14.1%, and it is 21.1% below its 52-week high.
₹ crore. Consolidated figures.
Transcript
Link of Recording
Indoco s Clinical Research Organisation AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities
The financial results for the period ended September 30, 2026.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 459 | 450 | 431 | 433 | 411 | 390 | 438 | 485 | 445 | 476 | 468 | 520 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 397 | 401 | 384 | 392 | 399 | 391 | 420 | 442 | 414 | 426 | 426 | 474 |
| Operating profit | 62.9 | 48.9 | 47.8 | 40.3 | 12.0 | −0.8 | 17.5 | 43.1 | 31.5 | 49.7 | 41.0 | 46.4 |
| Operating margin | 13.7% | 10.9% | 11.1% | 9.3% | 2.9% | -0.2% | 4.0% | 8.9% | 7.1% | 10.5% | 8.8% | 8.9% |
| Other income | 2.4 | 2.7 | 1.0 | 1.6 | 0.9 | 2.0 | 1.6 | 0.8 | 1.0 | −0.0 | 2.2 | 2.0 |
| Interest | 10.1 | 12.1 | 14.3 | 17.8 | 16.1 | 18.0 | 26.1 | 24.6 | 25.6 | 45.9 | 28.3 | 26.9 |
| Depreciation | 24.4 | 26.2 | 27.5 | 28.8 | 28.7 | 28.8 | 29.7 | 32.3 | 32.0 | 32.5 | 34.5 | 34.4 |
| Profit before tax | 22.6 | 33.0 | 7.0 | −4.8 | −31.0 | −45.5 | −36.7 | −13.5 | −31.3 | −25.0 | 77.7 | 24.2 |
| Tax | 7.1 | 11.0 | 5.2 | 5.2 | −2.6 | −4.2 | −0.3 | −4.3 | −1.9 | −1.3 | 12.3 | 4.7 |
| Net profit | 16.3 | 22.7 | 2.6 | −9.6 | −26.4 | −40.4 | −35.8 | −7.9 | −29.8 | −21.6 | 65.0 | 18.4 |
| EPS (₹) | 1.69 | 2.39 | 0.20 | -1.09 | -3.08 | -4.48 | -3.94 | -1.00 | -3.20 | -2.57 | 7.09 | 2.11 |
₹ crore, financial years to March.
| Line | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Sales | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,845 |
| Expenses | 983 | 1,017 | 1,213 | 1,383 | 1,573 | 1,566 | 1,704 |
| Operating profit | 123 | 224 | 327 | 286 | 244 | 99.3 | 142 |
| Operating margin | 11.1% | 18.1% | 21.2% | 17.1% | 13.4% | 6.0% | 7.7% |
| Other income | 2.4 | 3.1 | 2.3 | 2.3 | 9.9 | 5.5 | 3.3 |
| Interest | 26.3 | 22.3 | 14.1 | 25.0 | 38.0 | 66.2 | 122 |
| Depreciation | 70.8 | 73.1 | 79.0 | 70.6 | 91.9 | 114 | 126 |
| Profit before tax | 28.6 | 132 | 237 | 193 | 136 | −74.4 | −107 |
| Tax | 4.5 | 39.0 | 81.8 | 50.5 | 38.8 | 3.6 | −7.8 |
| Net profit | 24.1 | 93.1 | 155 | 103 | 98.5 | −73.7 | −95.2 |
| EPS (₹) | 2.62 | 10.10 | 16.80 | 15.44 | 10.52 | 8.46 | -10.70 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 1,028 | 1,110 | 1,022 | 939 | 1,022 |
| Borrowings | 333 | 672 | 994 | 1,036 | 976 |
| Total liabilities | 630 | 1,034 | 1,412 | 1,661 | 1,597 |
| Fixed assets | 612 | 788 | 849 | 970 | 929 |
| Investments | 1.5 | 1.5 | 1.5 | 1.5 | 5.3 |
| Cash and equivalents | 10.9 | 14.9 | 12.1 | 25.9 | 34.8 |
| Total assets | 1,658 | 2,145 | 2,430 | 2,593 | 2,613 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 174 | 94.9 | 192 | 185 |
| From investing | −121 | −339 | −102 | −49.2 |
| From financing | −44.4 | 241 | −76.8 | −126 |
| Spent on fixed assets | −125 | −356 | −148 | −60.5 |
| Free cash flow | 48.5 | −261 | 44.7 | 124 |
Margins, returns, debt, tax and cash.
| Line | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | 2.2% | 7.5% | 10.0% | 6.2% | 5.4% | -4.4% | -5.2% |
| Operating margin | 11.1% | 18.1% | 21.2% | 17.1% | 13.4% | 6.0% | 7.7% |
| Return on equity | – | – | – | 10.0% | 8.9% | -7.2% | -10.1% |
| Return on capital employed | – | – | – | 16.0% | 9.8% | -0.4% | 0.8% |
| Return on assets | – | – | – | 6.2% | 4.6% | -3.0% | -3.7% |
| Debt to equity | – | – | – | 0.32 | 0.61 | 0.97 | 1.10 |
| Interest coverage | 2.10 | 6.90 | 17.70 | 8.70 | 4.60 | -0.10 | 0.10 |
| Debt to assets | – | – | – | 0.20 | 0.31 | 0.41 | 0.40 |
| Current ratio | – | – | – | 1.90 | 1.56 | 1.24 | 1.13 |
| Quick ratio | – | – | – | 1.14 | 0.98 | 0.72 | 0.75 |
| Cash ratio | – | – | – | 0.03 | 0.02 | 0.01 | 0.02 |
| Asset turnover | – | – | – | 1.01 | 0.85 | 0.69 | 0.71 |
| Fixed asset turnover | – | – | – | 2.73 | 2.31 | 1.96 | 1.90 |
| Inventory turnover | – | – | – | – | 1.60 | 1.20 | 1.30 |
| Receivables turnover | – | – | – | 4.80 | 4.50 | 4.70 | 3.80 |
| Gross margin | – | – | – | – | 69.2% | 70.1% | 70.6% |
| Cash from operations to profit | – | – | 112.0% | – | – | – | – |
| Effective tax rate | 15.6% | 29.5% | 34.6% | 26.2% | 28.6% | – | – |
Allotment of 14850 securities pursuant to ESOP/ESPS at its meeting held on 27-10-2026 Shares.
Schedule of meet
Intimation to shareholders holding shares in physical mode regarding mandatory furnishing of PAN KYC and Bank details as per SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026
The incorporation of Wholly Owned subsidiary of the Company in the name and style of "Warren Lifesciences Private Limited .
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG rating
Approval of the Committee of Executive DIrectors for incorporation of the wholly owned subsidiary Warren Lifesciences Private Limited
A copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 17, 2026
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 UK MHRA inspection at Company''s manufacturing facility at Plant I (solid oral dosage form) located at Goa.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- USFDA Inspection at Company's manufacturing facility at Plant II (Sterile) located at Goa
Execution of Deed of Conveyance for Sale of Company's plot of land.